Shares of Abiomed Inc. (NASDAQ:ABMD) reached a new 52-week high on Tuesday . The stock traded as high as $110.78 and last traded at $109.05, with a volume of 230,314 shares changing hands. The stock had previously closed at $110.17.

Several analysts recently weighed in on ABMD shares. Jefferies Group restated a “buy” rating and set a $125.00 price target on shares of Abiomed in a report on Tuesday, March 22nd. Zacks Investment Research downgraded Abiomed from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 6th. Leerink Swann reaffirmed a “buy” rating on shares of Abiomed in a research report on Friday, April 8th. Finally, Benchmark Co. reaffirmed a “buy” rating and issued a $145.00 price objective on shares of Abiomed in a research report on Sunday, April 10th. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $111.98.

The stock has a 50-day moving average price of $102.22 and a 200-day moving average price of $92.40. The stock has a market cap of $4.73 billion and a price-to-earnings ratio of 131.11.

Abiomed (NASDAQ:ABMD) last announced its quarterly earnings data on Tuesday, May 3rd. The company reported $0.24 EPS for the quarter, topping the Zacks’ consensus estimate of $0.19 by $0.05. The company had revenue of $94 million for the quarter, compared to analysts’ expectations of $90.52 million. The business’s quarterly revenue was up 39.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.24 EPS. On average, analysts forecast that Abiomed Inc. will post $1.13 earnings per share for the current fiscal year.

In related news, COO David M. Weber sold 52,000 shares of Abiomed stock in a transaction that occurred on Thursday, May 5th. The stock was sold at an average price of $95.27, for a total transaction of $4,954,040.00. Following the transaction, the chief operating officer now owns 121,676 shares in the company, valued at $11,592,072.52. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Michael G. Howley sold 10,000 shares of Abiomed stock in a transaction that occurred on Wednesday, June 29th. The stock was sold at an average price of $106.58, for a total value of $1,065,800.00. Following the transaction, the vice president now owns 65,558 shares in the company, valued at approximately $6,987,171.64. The disclosure for this sale can be found here.

A number of institutional investors recently made changes to their positions in the company. Baillie Gifford & Co. bought a new position in shares of Abiomed during the fourth quarter worth approximately $25,947,000. Principal Financial Group Inc. increased its stake in Abiomed by 4.3% in the fourth quarter. Principal Financial Group Inc. now owns 262,842 shares of the company’s stock worth $23,729,000 after buying an additional 10,851 shares in the last quarter. Old Mutual Global Investors UK Ltd. increased its stake in Abiomed by 89.9% in the fourth quarter. Old Mutual Global Investors UK Ltd. now owns 183,183 shares of the company’s stock worth $16,537,000 after buying an additional 86,711 shares in the last quarter. Wells Fargo & Company MN increased its stake in Abiomed by 396.1% in the fourth quarter. Wells Fargo & Company MN now owns 179,883 shares of the company’s stock worth $16,240,000 after buying an additional 143,624 shares in the last quarter. Finally, Bank of Montreal Can increased its stake in Abiomed by 5.0% in the fourth quarter. Bank of Montreal Can now owns 168,969 shares of the company’s stock worth $15,255,000 after buying an additional 8,120 shares in the last quarter.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.